Dana-Farber Cancer Institute

Sorting 28 by

Accepting patients

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
  • CAR T Cell
  • GPRC5D
  • Phase 2

Accepting patients

SUCCESSOR-1

Phase 3 Clinical Trial Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Bortezomib and Dexamethasone Compared to Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
  • CELMoD
  • Randomization
  • Phase 3

Accepting patients

STOMP

Phase 1B / 2 Study of Selinexor in Combination With Other Treatments for Relapsed/Refractory and Newly Diagnosed Multiple Myeloma.
  • CELMoD
  • SINE
  • Phase 1/2
  • Has results

Accepting patients

BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
  • CAR T Cell
  • BCMA
  • GPRC5D
  • Phase 1

Accepting patients

CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
  • CAR T Cell
  • CELMoD
  • GPRC5D
  • Phase 1

Accepting patients

Daratumumab Combination Therapy

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
  • Monoclonal Antibody
  • Proteasome Inhibitor
  • CD38
  • Phase 2

Accepting patients

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
  • Autologous Stem Cell Transplant
  • CAR T Cell
  • BCMA
  • Phase 3

Not yet accepting

MagnetisMM-30

A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • CD3
  • Phase 1

Accepting patients

ISABELA

A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
  • Monoclonal Antibody
  • CD38
  • Quadruplet Therapy
  • Phase 2

Not yet accepting

Elranatamab as Consolidation

A Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • CD3
  • Phase 2
1 hidden based on your filters. Show All